Last reviewed · How we verify
NCT05573685
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training
NA trial testing DiNaMo Study App in Rheumatoid Arthritis in 124 participants. Completed in 6 February 2023.
6 February 2023
Quick facts
| Lead sponsor | Click Therapeutics, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 124 |
| Start date | 10 October 2022 |
| Primary completion | 6 February 2023 |
| Estimated completion | 6 February 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- DiNaMo Study App
- Placebo App
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
- Diabetic Neuropathy — all drugs for Diabetic Neuropathy →
- Fibromyalgia — all drugs for Fibromyalgia →
- Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →
Sponsor
Click Therapeutics, Inc.
Who can join
Adults 18 to 65, any sex, with Rheumatoid Arthritis or Diabetic Neuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc. (Click).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05573685
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other Click Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT06486948 — An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-1 · NA · completed
- NCT06275659 — An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis · NA · completed
- NCT06136923 — An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer · NA · completed
- NCT06136936 — A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia · NA · completed
- NCT06067984 — An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Sc · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05573685 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Click Therapeutics, Inc.
- Last refreshed: 26 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05573685.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing